Skip to main content
Fig. 7 | Clinical Epigenetics

Fig. 7

From: The epigenetic modifier JMJD6 is amplified in mammary tumors and cooperates with c-Myc to enhance cellular transformation, tumor progression, and metastasis

Fig. 7

JMJD6 binds to the p19ARF promoter and decreases histone H4R3 asymmetric dimethylation of the p19ARF promoter. ChIP analysis of the p19ARF promoter in NMuMG cells expressing LacZ, JMJD6, or JMJD6 mutant using immunoprecipitation with a anti-H4R4me2a, b anti-JMJD6 antibody, c V5-conjugated agarose. d ChIP analysis of HeLa cells shows binding of endogenous JMJD6 to the human p14ARF promoter. Two different primer sets (distal and proximal) were used for qPCR after immunoprecipitation. Primers for human β-globin gene promoter were used as a positive control

Back to article page

Clinical Epigenetics

ISSN: 1868-7083

Contact us